Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Geron reports positive trial results and financial strength for growth

Geron's Q4 2022 earnings call showcases promising developments in clinical trials and strategic commercialization plans. While facing increased expenses and challenges in trial enrollment and regulatory processes, the company remains well-positioned with a solid financial foundation and opportunities for growth.

Geron reports strong Q1 performance, eyes global expansion opportunities

Geron's Q1 performance reflects optimism around Imetelstat's potential in MDS and myelofibrosis treatment.
Strong financial resources and strategic market positioning provide a foundation for sales expansion and growth.
While challenges exist in pricing and market adoption, Geron is poised to capitalize on opportunities for global expansion.

Geron reports progress with imetelstat in lower-risk MDS

Geron's Q2 call highlighted imetelstat's potential in lower-risk MDS, with a focus on commercial readiness and financial updates. Challenges include addressing physician concerns and managing rising expenses.

Geron progresses towards FDA approval for imetelstat in 2024

Geron is on track for FDA approval of imetelstat in late 2024, supported by a robust financial position and strategic commercialization plans.
The company's focus on transfusion independence and positive market feedback highlight the potential market success of imetelstat.
Challenges in dosing, mutation efficacy, and partnership opportunities require careful navigation for successful market penetration.
Physician adoption and patient switching dynamics present opportunities for imetelstat to gain market share and establish itself as a valuable treatment option.

Geron poised for FDA approval of imetelstat, eyes $7B market

Geron's Q4 2023 earnings call highlighted strong financials, positive trial results for imetelstat, and upcoming regulatory milestones in 2024. While facing challenges related to safety assessments and physician education, the company is well-positioned to capitalize on the substantial market opportunity for imetelstat.

Geron poised for U.S. launch of imetelstat with FDA support

Geron's strong financial position and FDA support bode well for the potential approval and successful U.S. launch of imetelstat. While facing challenges in clinical development timelines and patent decisions, the company is poised to address unmet needs and create commercial value. Opportunities in new markets and extended exclusivity offer avenues for growth and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte

Formed in the early ‘90s, Geron and Incyte exemplify the long and often tumultuous road it takes to translate science into medicines.

Better Buy: Geron vs. Incyte

Geron (GERN) reported earnings 30 days ago. What's next for the stock?

Geron (GERN) Up 2.4% Since Last Earnings Report: Can It Continue?

Almaden Minerals

Ambev

Babcock & Wilcox Enterprises

Paratek Pharma

Synacor

While trade relations and tax-loss selling are causes for concern, opportunities for short-term and swing traders remain abundant.

Penny Stocks to Buy Using Technical Analysis for December 2019

Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?

Geron Corporation (GERN) CEO John Scarlett on Q3 2019 Results - Earnings Call Transcript

Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.

Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%

New Age Beverages

Senseonics Holdings

ViewRay

Written by: Craig Adeyanju | FinScreener Penny stocks, on the surface, look attractive because they generally have prices under $5. However, many penny stocks belong in that category for a reason and one of them is that they typically lack the trading volume required for them to be attractive to traders.

4 Best High Volume Penny Stocks To Consider

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Geron (GERN) Q3 Earnings Expected to Decline

Celgene

Which stock wins between these two biotechs?

Better Buy: Geron Corporation vs. Celgene Corporation

Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.

Geron Starts Enrollment in Phase III MDS Study on Imetelstat

MENLO PARK, Calif., Oct.  10, 2019  (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).

Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.

Geron's Imetelstat Gets Fast Track Status for Myelofibrosis

Geron announced an important regulatory win today.

Why Geron Stock Is Jumping Today

MENLO PARK, Calif., Sept.  30, 2019  (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the treatment of adult patients with Intermediate-2 or High-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment, or relapsed/refractory MF. The Fast Track designation includes patients with primary MF and MF developed after essential thrombocythemia or polycythemia vera. This is the same patient population that was studied in Geron’s IMbark Phase 2 clinical trial. There are currently no marketed drugs specifically approved for relapsed/refractory MF, representing a significant unmet medical need. Geron plans to conduct an End of Phase 2 meeting with the FDA by the end of the first quarter of 2020 to determine if there is a regulatory path forward for imetelstat in relapsed/refractory MF.

Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis

MENLO PARK, Calif., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 2019 Cantor Global Healthcare Conference in New York at 9:30 a.m. ET on Friday, October 4, 2019.

Geron to Present at 2019 Cantor Global Healthcare Conference

Denali Therapeutics

Here's why shares of these drugmakers have a very slim chance to provide anything but losses.

2 Biotech Stocks I Wouldn't Touch With a Broom

Why Is Geron (GERN) Up 21.7% Since Last Earnings Report?

Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why

Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.

Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss

There wasn't much good news for the small biotech in Q2. But Geron continues to plug away with its imetelstat program.

What You'll Want to Know About Geron's Q2 Results

Geron Corp (GERN) CEO John Scarlett on Q2 2019 Results - Earnings Call Transcript

Geron (GERN) delivered earnings and revenue surprises of -33.33% and -49.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Geron (GERN) Reports Q2 Loss, Misses Revenue Estimates

Geron's stock has rebounded nicely in the first half of 2019.

Why Geron Corporation Stock Bolted Higher in the First Half of 2019

Why Is Geron (GERN) Down 22% Since Last Earnings Report?

Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

News for Geron Stock (GERN)